Elanco Animal Health Inc
Elanco Animal Health is a U.S.-based animal health company that develops and sells medicines, vaccines, feed additives and related services for pets and farm animals. Its portfolio spans dogs and cats as well as cattle, poultry, swine and sheep, with sales in more than 90 countries through veterinarians, distributors, retailers and farm producers.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueProducts sold for dogs and cats, including flea, tick and other companion-animal therapies.
Products for cattle, poultry, swine and sheep used to prevent and treat disease and improve productivity.
Products such as Bovaer that support animal performance and emissions reduction in livestock systems.
Scientific consulting, training, education and data analytics offered alongside product sales.
Products
Reported · share of revenue- Pet Health48.8 %
- Cattle23.9 %
- Poultry18.2 %
- Swine8.0 %
- Contract Manufacturing1.1 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Elanco sells to a mix of distributors, retailers, veterinarians and direct farm producers, so its demand is split between companion-animal and livestock channels. Pet health products are typically purchased by distributors, retailers and veterinarians for resale to pet owners, while farm animal products are bought by producers and distributors to support herd and flock health and productivity.
Buy companion-animal products and some farm animal therapies, and influence product choice through prescribing and education.
Purchase pet health products for resale through clinic, retail and e-commerce channels.
Beef, dairy, pork and poultry operations buy products to prevent disease and improve productivity.
End customers for flea, tick and other companion-animal products, usually reached indirectly through vets and retailers.
Large purchasing organizations that negotiate pricing and can pressure margins.
Strategy
Elanco’s strategy centers on revenue growth through portfolio development, product innovation and lifecycle management of existing brands. The company is also expanding omnichannel access across veterinary, retail and e-commerce channels while using its sales force, consultants and data analytics to deepen customer relationships and support adoption of new products.
New molecules, registrations and indications are needed to offset mature brands and sustain growth.
Top products contribute a large share of revenue, so extending their commercial life protects the base business.
Pet health demand is shifting toward retail and e-commerce, so channel coverage is critical to preserve share.
Geography
Q1/2026Elanco sells its portfolio in more than 90 countries, making it a globally diversified animal-health business rather than a single-market supplier. The company highlighted international farm-animal demand, including strength in poultry and swine and accelerated customer purchases in China ahead of tariff expectations, showing that trade policy and regional livestock cycles can affect quarterly results.
Share of the revenue the company reports by geography.
Risks
Elanco faces competitive pressure, regulatory risk and channel disruption risk because its products depend on veterinarian adoption, distributor access and ongoing approvals. Concentration in a few top brands, customer consolidation and exposure to trade/tariff dynamics can all amplify the impact of product, pricing or demand shocks.
- Regulatory approval and product safety riskImpact: HighLikelihood: High
New products and new indications require approvals and can face delays, warning labels or adoption setbacks.
Exposure: Bovaer experienced a lengthy FDA review and initial adoption was slowed by warning language.
- Dependence on top productsImpact: HighLikelihood: Medium
Advantage Family, Seresto, Credelio Family, Rumensin and Maxiban/Monteban represented a large share of revenue, so any loss of demand or patent protection would be meaningful.
Exposure: Top five products and/or product families represented approximately 38% of total revenue in 2025.
- Channel shift away from veterinariansImpact: MediumLikelihood: Medium
Pet owners increasingly buy through online, big-box and specialty channels, which can lower margins and weaken clinic-based sales.
Exposure: Flea and tick products are especially exposed to channel migration.
- Trade and tariff volatilityImpact: MediumLikelihood: Medium
International farm-animal demand can be pulled forward or delayed by tariff expectations and policy changes.
Exposure: China-related accelerated purchases were noted in 2025.
- Customer and distributor consolidationImpact: Medium
Larger buying groups can use scale to negotiate lower prices and reduce Elanco’s margins.
Exposure
Accounting
Judgemental itemsSales flow through distributors, retailers, veterinarians and direct farm customers, so timing and channel mix can affect when revenue is recorded.
Impact: Quarterly comparability and channel mix analysis
Management uses forecast cash flows, margins and discount rates to test the single reporting unit for impairment.
Impact: Potential non-cash charges if expectations weaken
The aqua business divestiture required allocation of goodwill and fair value estimates.
Impact: Gain or loss on disposal and balance sheet adjustments
Forecasts for revenue growth, gross margin and EBITDA margin are central to valuation and impairment analyses.
Impact: Reported earnings and asset values
Similar listed companies
Publicly listed companies with a comparable business focus.
Phibro Animal Health Corporation
PAHC · Pharmaceutical Preparations
Merck & Co., Inc.
MRK · Pharmaceutical Preparations
Zoetis Inc.
ZTS · Pharmaceutical Preparations
Petco Health & Wellness Company, Inc.
WOOF · Retail-Retail Stores, NEC
The Mosaic Company
MOS · Agricultural Chemicals
Shineco, Inc.
Agricultural Production-Crops
Last updated: 24/09/2026